These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 9488597

  • 1. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [Abstract] [Full Text] [Related]

  • 2. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg ME, Luyten GP, de Leeuw K, de Boer-Dennert M, Wissel PS, Jewell RC, Paul EM, Purvis NB, Verweij J.
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
    [Abstract] [Full Text] [Related]

  • 3. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.
    Punt CJ, Voest EE, Tueni E, Van Oosterom AT, Backx A, De Mulder PH, Hecquet B, Lucas C, Gerard B, Bleiberg H.
    Br J Cancer; 1997 Jan; 76(10):1376-81. PubMed ID: 9374386
    [Abstract] [Full Text] [Related]

  • 4. Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial.
    Stupp R, Bauer J, Pagani O, Gerard B, Cerny T, Sessa C, Bastian G, Sarkany M, Schläpfer J, Giroux B, Leyvraz S.
    Ann Oncol; 1998 Nov; 9(11):1233-42. PubMed ID: 9862055
    [Abstract] [Full Text] [Related]

  • 5. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
    Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J, Harding MW, Von Hoff DD.
    J Clin Oncol; 1998 Sep 01; 16(9):2964-76. PubMed ID: 9738565
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
    Mross K, Niemann B, Massing U, Drevs J, Unger C, Bhamra R, Swenson CE.
    Cancer Chemother Pharmacol; 2004 Dec 01; 54(6):514-24. PubMed ID: 15322827
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC, Whitfield LR, Grove WR, Rummel S, Grochow LB, Donehower RC.
    Clin Cancer Res; 2000 Oct 01; 6(10):3885-94. PubMed ID: 11051234
    [Abstract] [Full Text] [Related]

  • 10. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243).
    Sessa C, Zucchetti M, Ghielmini M, Bauer J, D'Incalci M, de Jong J, Naegele H, Rossi S, Pacciarini MA, Domenigoni L, Cavalli F.
    Cancer Chemother Pharmacol; 1999 Oct 01; 44(5):403-10. PubMed ID: 10501914
    [Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL, Tseng YL.
    Cancer; 2001 May 01; 91(9):1826-33. PubMed ID: 11335910
    [Abstract] [Full Text] [Related]

  • 12. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG, Balcerzak SP, Kraut EH.
    Cancer Res; 1993 Oct 15; 53(20):4843-9. PubMed ID: 8402671
    [Abstract] [Full Text] [Related]

  • 13. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW, O'Shaughnessy JA, Weiss RB, Zujewski J, Myhand RC, Schneider E, Hakim F, Gress R, Goldspiel B, Noone MH, Brewster LR, Gossard MR, Cowan KH.
    Clin Cancer Res; 1997 May 15; 3(5):755-60. PubMed ID: 9815746
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R.
    Anticancer Res; 2000 May 15; 20(1B):485-91. PubMed ID: 10769710
    [Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 18. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P.
    Cancer Res; 1993 Oct 15; 53(20):4837-42. PubMed ID: 8402670
    [Abstract] [Full Text] [Related]

  • 19. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I, Bench K, Beijnen JH, Bruntsch U, Cavalli F, de Jong J, Groot Y, van Tellingen O, Wanders J, Sessa C.
    Clin Cancer Res; 1996 Oct 15; 2(10):1717-23. PubMed ID: 9816122
    [Abstract] [Full Text] [Related]

  • 20. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
    Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, Mascorro D, Abrahams T, Von Hoff DD.
    Cancer Chemother Pharmacol; 1999 Oct 15; 44(5):372-80. PubMed ID: 10501910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.